Cargando…
Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer
HER-2 positive tumors are among the most aggressive subtypes of breast cancer and are frequently associated with metastasis and poor outcome. As with other aggressive subtypes of breast cancer, these tumors are associated with abnormally high expression of galectin-7 (gal-7), which confers metastati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130216/ https://www.ncbi.nlm.nih.gov/pubmed/27902734 http://dx.doi.org/10.1371/journal.pone.0166731 |
_version_ | 1782470695050018816 |
---|---|
author | Grosset, Andrée-Anne Poirier, Françoise Gaboury, Louis St-Pierre, Yves |
author_facet | Grosset, Andrée-Anne Poirier, Françoise Gaboury, Louis St-Pierre, Yves |
author_sort | Grosset, Andrée-Anne |
collection | PubMed |
description | HER-2 positive tumors are among the most aggressive subtypes of breast cancer and are frequently associated with metastasis and poor outcome. As with other aggressive subtypes of breast cancer, these tumors are associated with abnormally high expression of galectin-7 (gal-7), which confers metastatic breast tumor cells with increased invasive behavior. Although previous studies in the rat model of breast tumorigenesis have shown that gal-7 is also increased in primary breast tumor, its contribution to the development of the primary breast tumors remains unclear. In the present work, we have used genetically-engineered gal-7-deficient mice to examine the role of gal-7 in the development of the mammary gland and of breast cancer. Using histological and immunohistological analysis of whole mammary glands at different stages of development, we detected no significant changes between normal and gal-7-deficient mice. To test the involvement of gal-7 in breast cancer, we next examined the effects of loss of gal-7 on mammary tumor development by crossing gal-7-deficient mice with the mammary tumor transgenic mouse strain FVB-Tg(MMTV-Erbb2)NK1Mul/J. Finally, assessment of mice survival and tumor volume showed a delay of mammary tumor growth in the absence of systemic gal-7. These data suggest that gal-7 could potentiate the phenotype of HER-2 positive primary breast cancer. |
format | Online Article Text |
id | pubmed-5130216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-51302162016-12-15 Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer Grosset, Andrée-Anne Poirier, Françoise Gaboury, Louis St-Pierre, Yves PLoS One Research Article HER-2 positive tumors are among the most aggressive subtypes of breast cancer and are frequently associated with metastasis and poor outcome. As with other aggressive subtypes of breast cancer, these tumors are associated with abnormally high expression of galectin-7 (gal-7), which confers metastatic breast tumor cells with increased invasive behavior. Although previous studies in the rat model of breast tumorigenesis have shown that gal-7 is also increased in primary breast tumor, its contribution to the development of the primary breast tumors remains unclear. In the present work, we have used genetically-engineered gal-7-deficient mice to examine the role of gal-7 in the development of the mammary gland and of breast cancer. Using histological and immunohistological analysis of whole mammary glands at different stages of development, we detected no significant changes between normal and gal-7-deficient mice. To test the involvement of gal-7 in breast cancer, we next examined the effects of loss of gal-7 on mammary tumor development by crossing gal-7-deficient mice with the mammary tumor transgenic mouse strain FVB-Tg(MMTV-Erbb2)NK1Mul/J. Finally, assessment of mice survival and tumor volume showed a delay of mammary tumor growth in the absence of systemic gal-7. These data suggest that gal-7 could potentiate the phenotype of HER-2 positive primary breast cancer. Public Library of Science 2016-11-30 /pmc/articles/PMC5130216/ /pubmed/27902734 http://dx.doi.org/10.1371/journal.pone.0166731 Text en © 2016 Grosset et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Grosset, Andrée-Anne Poirier, Françoise Gaboury, Louis St-Pierre, Yves Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title | Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title_full | Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title_fullStr | Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title_full_unstemmed | Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title_short | Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer |
title_sort | galectin-7 expression potentiates her-2-positive phenotype in breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130216/ https://www.ncbi.nlm.nih.gov/pubmed/27902734 http://dx.doi.org/10.1371/journal.pone.0166731 |
work_keys_str_mv | AT grossetandreeanne galectin7expressionpotentiatesher2positivephenotypeinbreastcancer AT poirierfrancoise galectin7expressionpotentiatesher2positivephenotypeinbreastcancer AT gabourylouis galectin7expressionpotentiatesher2positivephenotypeinbreastcancer AT stpierreyves galectin7expressionpotentiatesher2positivephenotypeinbreastcancer |